Polymeric micelles as mighty nanocarriers for cancer gene therapy: a review Mahsa Yousefpour MarzbaliAhmad Yari Khosroushahi Review Article 17 March 2017 Pages: 637 - 649
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041) Naoya YamazakiTatsuya TakenouchiKenji Yokota Original Article Open access 11 March 2017 Pages: 651 - 660
An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism Ka WangFranziska Schaedeli StarkOliver Krieter Original Article 17 March 2017 Pages: 661 - 671
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors Anthony W. TolcherJordan D. BerlinDavid S. Hong Original Article 09 March 2017 Pages: 673 - 680
Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients D. MahadevanMonica MitaAung Naing Original Article 13 March 2017 Pages: 681 - 688
Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003) Akito HataNobuyuki KatakamiShunichi Negoro Original Article 09 March 2017 Pages: 689 - 695
A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma Devalingam MahalingamChristos FountzilasJohn Sarantopoulos Original Article 13 March 2017 Pages: 697 - 703
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease Kosuke KashiwabaraHiroshi SembaShinsuke Tsumura Original Article 03 March 2017 Pages: 705 - 710
In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension Bethany BaumgartMausumee GuhaRoderick Todd Bunch Original Article 10 March 2017 Pages: 711 - 723
Synthesis of short retinoidal amides related to fenretinide: antioxidant activities and differentiation-inducing ability Maria AnzaldiMaurizio VialeAlessandro Balbi Original Article 09 March 2017 Pages: 725 - 736
hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia Islem Ben HassineHanene GharbiSamia Menif Original Article 12 March 2017 Pages: 737 - 745
The influence of TNF-α and Ang II on the proliferation, migration and invasion of HepG2 cells by regulating the expression of GRK2 Zhou-wei XuShang-xue YanWei Wei Original Article 18 March 2017 Pages: 747 - 758
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study Mahamadou TandiaAsma MhiriLaurence Bonhomme-Faivre Original Article 13 March 2017 Pages: 759 - 766
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia Laura GaleottiFrancesco CeccheriniSara Galimberti Original Article 13 March 2017 Pages: 767 - 773
A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma Naru KondoYoshiaki MurakamiTaijiro Sueda Original Article 14 March 2017 Pages: 775 - 781
Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38 Yurie KatsubeMasayuki TsujimotoKohshi Nishiguchi Original Article 17 March 2017 Pages: 783 - 789
XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies Tianxin XiangXiuhua KangWei Zhang Original Article 17 March 2017 Pages: 791 - 800
Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact Yoshiaki MurakamiKenichiro UemuraTaijiro Sueda Original Article 17 March 2017 Pages: 801 - 811
Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer Hiroki YamaueAtsushi ShimizuTetsuhiko Shirasaka Clinical Trial Report 01 March 2017 Pages: 813 - 823
The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer Jia ZhouFei DongXiaokui Tang Clinical Trial Report 13 March 2017 Pages: 825 - 833
Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil Chengyu HongJian ZhengXiaoling Li Short Communication 17 March 2017 Pages: 835 - 840
Reply: Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect Victoria J. ForsterFrederik W. van DelftChristina Halsey Letter to the Editor 13 March 2017 Pages: 841 - 842
